Unknown

Dataset Information

0

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

ABSTRACT: Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

SUBMITTER: Mohammed AA 

PROVIDER: S-EPMC6683209 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Mohammed Amrallah A AA   Rashied Hanaa H   Elsayed Fifi Mostafa FM  

Oncology reviews 20190729 2

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation. ...[more]

Similar Datasets

Unknown CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
| S-EPMC6299331 | biostudies-literature
Unknown Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.
| S-EPMC5704690 | biostudies-literature
Unknown CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
| S-EPMC6424488 | biostudies-literature
Unknown HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
| S-EPMC5652078 | biostudies-literature
Unknown Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.
| S-EPMC4697745 | biostudies-literature
Unknown Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
| S-EPMC7554788 | biostudies-literature
Unknown Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
| S-EPMC7237121 | biostudies-literature
Unknown The role of CDK4/6 inhibitors in early breast cancer.
| S-EPMC8184648 | biostudies-literature
Unknown Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
| S-EPMC8257068 | biostudies-literature
Unknown Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
| S-EPMC8313476 | biostudies-literature